Share Price:

APNASPENAspen Pharmacare Hldgs961032 (0.33%)

Aspen delivers double digit organic growth in normalised EBITDA, operating profit and earnings

Johannesburg โ€“ JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is pleased to report reviewed provisional Group financial results for the year ended 30 June 2022. ย  SALIENT FEATURES Revenue from continuing operations increased by 2% (+5% in constant exchange rate (โ€œCERโ€)) to R38,6 billion (FY2021: R37,8 billion); Normalised EBITDA from… Continue reading Aspen delivers double digit organic growth in normalised EBITDA, operating profit and earnings

Aspen concludes a collaboration agreement to manufacture and make available four Aspen-branded vaccines for Africa.

Durban, South Africaย –ย JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company,ย is pleased to announce that one of its wholly-owned South African subsidiaries, Aspen SAย Operations (Pty) Limited (โ€œAspen SA Operationsโ€), has concluded a ten-year agreement (โ€œthe Agreementโ€) withย Serum Institute of India Pvt Ltd (โ€œthe Serum Instituteโ€), the worldโ€™s largest vaccine producer,… Continue reading Aspen concludes a collaboration agreement to manufacture and make available four Aspen-branded vaccines for Africa.

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.